Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes

AIM: To evaluate the efficacy and safety of twice‐daily insulin degludec/insulin aspart vs. twice‐daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naïve to insulin. METHODS: In this 26‐week, multinational, open‐label, controlled, two‐arm, parallel‐group, treat‐to‐tar...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Diabet Med
Hoofdauteurs: Franek, E., Haluzík, M., Canecki Varžić, S., Sargin, M., Macura, S., Zacho, J., Christiansen, J. S.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2015
Onderwerpen:
Research Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5063147/
https://ncbi.nlm.nih.gov/pubmed/26435365
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dme.12982
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items